Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Enrico L. DiGiammarino"'
Autor:
David Maag, Eric F. Johnson, Donald J. Osterling, DeAnne F. Stolarik, Amanda M. Olson, Wenqing Gao, Julie L. Wilsbacher, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Larry R. Solomon, Luis E. Rodriguez, Yan Shi, Todd A. Hopkins
Supplementary figures S1-S6, tables 1 and 2. Table S1. Body weight loss and health observations in HeyA8 xenograft tumor-bearing mice treated with PARP inhibitors or TMZ alone or in combination. Table S2. Summary of PK parameters in HeyA8 xenograft t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bcfa08a35c000c13a490792d1596a75
https://doi.org/10.1158/1541-7786.22514481.v1
https://doi.org/10.1158/1541-7786.22514481.v1
Autor:
David Maag, Julie L. Wilsbacher, Eric F. Johnson, Amanda M. Olson, Yan Shi, Mikkel A. Algire, Vivek C. Abraham, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Paul A. Ellis, William B. Ainsworth, Todd A. Hopkins
Association of PARP1 and H2A.X detected by Proximity Ligation Assay (PLA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d490333306545aace2682f34c3fb2b1
https://doi.org/10.1158/1541-7786.22514785.v1
https://doi.org/10.1158/1541-7786.22514785.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948fdfba3f05b8a422e19034176fe36d
https://doi.org/10.1158/1535-7163.22505686
https://doi.org/10.1158/1535-7163.22505686
Autor:
David Maag, Julie L. Wilsbacher, Eric F. Johnson, Amanda M. Olson, Yan Shi, Mikkel A. Algire, Vivek C. Abraham, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Paul A. Ellis, William B. Ainsworth, Todd A. Hopkins
Association of PARP1 and other histone proteins detected by Proximity Ligation Assay (PLA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a73200cd0e0b2826cfb29f9594a526
https://doi.org/10.1158/1541-7786.22514782
https://doi.org/10.1158/1541-7786.22514782
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ca9367d459176dea46bdd55158c64
https://doi.org/10.1158/1535-7163.22505689.v1
https://doi.org/10.1158/1535-7163.22505689.v1
Autor:
David Maag, Julie L. Wilsbacher, Eric F. Johnson, Amanda M. Olson, Yan Shi, Mikkel A. Algire, Vivek C. Abraham, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Paul A. Ellis, William B. Ainsworth, Todd A. Hopkins
IC50 values of PARPi vs BM-CFU and BM-PAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17a64aa11e2b2967e2f843fb56859904
https://doi.org/10.1158/1541-7786.22514773
https://doi.org/10.1158/1541-7786.22514773
Autor:
David Maag, Julie L. Wilsbacher, Eric F. Johnson, Amanda M. Olson, Yan Shi, Mikkel A. Algire, Vivek C. Abraham, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Paul A. Ellis, William B. Ainsworth, Todd A. Hopkins
Clinical RP2D concentrations for PARP inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4316ce74d1ccc2bcb5ea88f60741cf
https://doi.org/10.1158/1541-7786.22514776.v1
https://doi.org/10.1158/1541-7786.22514776.v1
Autor:
David Maag, Julie L. Wilsbacher, Eric F. Johnson, Amanda M. Olson, Yan Shi, Mikkel A. Algire, Vivek C. Abraham, Sanjay C. Panchal, Enrico L. DiGiammarino, Cherrie K. Donawho, Paul A. Ellis, William B. Ainsworth, Todd A. Hopkins
Bone Marrow IC50s broken into cell type.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e498c80f13b9c6f3eef5213b00c9a4
https://doi.org/10.1158/1541-7786.22514770
https://doi.org/10.1158/1541-7786.22514770
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2454e519448df5024c51607be68974ce
https://doi.org/10.1158/1535-7163.c.6538150.v1
https://doi.org/10.1158/1535-7163.c.6538150.v1
Autor:
Deborah Widomski, Vivek C. Abraham, Darren C. Phillips, Fritz G. Buchanan, Zhihong Liu, Stephen K. Tahir, Haichao Zhang, John Xue, Nandini Rudra-Ganguly, Xin Lu, Dong Cheng, Enrico L. Digiammarino, Morey L. Smith, Yu Xiao, Larry R. Solomon, Susan E. Morgan-Lappe, Bruce Trela, Nan Xu, Li Zhou
Publikováno v:
Cancer Research. 81:3402-3414
TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa (ABBV-621) is a second generation TRAIL receptor agonist engineered as an IgG1-Fc mutant backbon